IceCure Medical Ltd. (NASDAQ:ICCM) Short Interest Update

IceCure Medical Ltd. (NASDAQ:ICCM) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 107,730 shares, an increase of 164.2% from the August 15th total of 40,780 shares. Currently, 3.2% of the shares of the stock are short sold. Based on an average daily volume of 218,702 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Zacks Research cut shares of IceCure Medical from a “hold” rating to a “strong sell” rating in a research note on Friday, August 14th. Wall Street Zen raised shares of IceCure Medical from a “sell” rating to a “hold” rating in a report on Saturday, September 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a research report on Friday, July 17th. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $52.50.

IceCure Medical Price Performance

Shares of IceCure Medical stock traded down $0.00 during trading on Tuesday, hitting $2.09. The stock had a trading volume of 11,360 shares, compared to its average volume of 1,203,506. IceCure Medical has a 12 month low of $2.04 and a 12 month high of $42.00. The firm’s fifty day simple moving average is $2.88 and its 200-day simple moving average is $7.44. The stock has a market cap of $7.15 million, a PE ratio of -0.25 and a beta of 0.45.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($1.60) EPS for the quarter. The firm had revenue of $0.91 million for the quarter. IceCure Medical had a negative net margin of 427.67% and a negative return on equity of 174.26%. Analysts expect that IceCure Medical will post -4.61 earnings per share for the current fiscal year.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.